Anupam Rasayan: consolidated PAT +14% YoY on M&A scale-up; standalone revenue -32%
PAT +13.68% YoY · revenue +10.19% · margins expanding
₹805.94 Cr
+10.19% YoY
₹64.97 Cr
+13.68% YoY
7.91%
+0.2pp YoY
₹6.81
Anupam Rasayan's consolidated PAT (profit after tax for the period, pre-minority) was ₹64.97 Cr in Q2 FY27, up 13.7% YoY from ₹57.15 Cr and up 26.9% QoQ from ₹51.22 Cr; profit attributable to owners was ₹50.03 Cr (basic EPS ₹6.81 versus ₹3.93 a year ago). Consolidated revenue was ₹805.94 Cr, up 10.2% YoY and 23.1% QoQ. The YoY comparison isn't like-for-like, though: Jayhawk Fine Chemicals (US, acquired effective February 27, 2026) wasn't fully in the year-ago consolidation base, so a meaningful share of the reported YoY growth is inorganic rather than organic volume growth.
Q2 FY-2027 vs prior quarters
The standalone (parent-only) numbers tell a different story. Standalone revenue fell 32.4% YoY to ₹397.19 Cr from ₹587.93 Cr, yet standalone PAT still rose 10.3% YoY to ₹45.65 Cr because cost of materials consumed fell even faster than revenue, pushing standalone OPM to 31.6% from 18.6% a year ago — a richer revenue mix rather than volume growth, with the year-ago quarter likely carrying a large, lower-margin order. At the consolidated level, OPM was 23.2%, expanding from 18.6% YoY but compressing from 24.8% in Q1 FY27; NPM was 7.9%, modestly ahead of both the prior quarter (7.7%) and year-ago quarter (7.7%). Non-controlling interests absorbed ₹14.94 Cr of the ₹64.97 Cr consolidated PAT, reflecting the partly-owned Tanfac, Jayhawk and now Bliss GVS Pharma structure.
The stock went into the print at ₹1,162.9, down 0.2% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
FY27 organic revenue growth 25% ± couple points; standalone EBITDA 24-26%, consolidated 22-24%; capex INR 70-80 Cr. Expect working capital improvement; order book to contribute 25-30% of revenue.
— This quarter: missed
Management's August 2026 guidance called for FY27 organic revenue growth of 25% ± a couple of points, standalone EBITDA margin of 24-26% and consolidated EBITDA margin of 22-24%. The margin targets were met or beaten this quarter (standalone 31.6%, consolidated 23.2%), but the growth target was missed by a wide margin — consolidated revenue grew only 10.2% YoY and leaned on acquisitions rather than organic volumes, while standalone (the core organic business) revenue actually contracted. We found no quarter-specific Street consensus to benchmark this print against. The quarter's biggest corporate event — the ₹1,750 Cr, 48.2%-stake acquisition of Bliss GVS Pharma, effective September 28, 2026 — barely touched this quarter's P&L (3 days consolidated, ~₹1.2 Cr PAT) but added ₹10,224 Cr of provisional goodwill to the balance sheet; its first full quarter of contribution, alongside a full-year Jayhawk contribution, falls in Q3 FY27.
W1
First full quarter of Bliss GVS Pharma consolidation in Q3 FY27, against management's pro-forma group revenue guidance of ₹4,000+ Cr annualised (Anupam standalone ~₹1,676 Cr + Tanfac ~₹711 Cr + Jayhawk ~₹722 Cr + Bliss GVS ~₹927 Cr)
W2
Whether consolidated revenue growth closes the gap to management's 25% organic FY27 target — H1 FY27 growth is tracking well below that, and much of it is inorganic
W3
Durability of standalone's 31.6% OPM (up from 18.6% YoY) — watch whether this margin jump holds or reverts as order mix normalises
Informational and educational content only. Not investment advice.